About RNA-binding protein Nova-1
RNA-binding protein Nova-1 (NOVA1) is a protein
from Homo sapiens identified by UniProt accession
P51513, 507 residues long.
MolForge cross-references it against 0 known binders and
114 disease associations.
Target properties
| Protein name | RNA-binding protein Nova-1 |
| UniProt accession | P51513 |
| Gene | NOVA1 |
| Organism | Homo sapiens |
| Length | 507 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (114)
Diseases linked to this target (Open Targets).
- self reported educational attainment · score 0.48
- cognitive function measurement · score 0.42
- cortical surface area measurement · score 0.31
- mathematical ability · score 0.31
- lifestyle measurement · score 0.31
- sleep duration · score 0.31
- intelligence · score 0.31
- sodium measurement · score 0.29
- age at first birth measurement · score 0.27
- brain measurement · score 0.25
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P51513-F1 | alphafold | PREDICTED | 62.66 | — |
Amino-acid sequence (507 residues)
MMAAAPIQQN GTHTGVPIDL DPPDSRKRPL EAPPEAGSTK RTNTGEDGQY FLKVLIPSYA AGSIIGKGGQ TIVQLQKETG ATIKLSKSKD FYPGTTERVC LIQGTVEALN AVHGFIAEKI REMPQNVAKT EPVSILQPQT TVNPDRIKQT LPSSPTTTKS SPSDPMTTSR ANQVKIIVPN STAGLIIGKG GATVKAVMEQ SGAWVQLSQK PDGINLQERV VTVSGEPEQN RKAVELIIQK IQEDPQSGSC LNISYANVTG PVANSNPTGS PYANTAEVLP TAAAAAGLLG HANLAGVAAF PAVLSGFTGN DLVAITSALN TLASYGYNLN TLGLGLSQAA ATGALAAAAA SANPAAAAAN LLATYASEAS ASGSTAGGTA GTFALGSLAA ATAATNGYFG AASPLAASAI LGTEKSTDGS KDVVEIAVPE NLVGAILGKG GKTLVEYQEL TGARIQISKK GEFVPGTRNR KVTITGTPAA TQAAQYLITQ RITYEQGVRA ANPQKVG
Explore RNA-binding protein Nova-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets